Cannabis and Dermatitis

This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.

Plain-language summary

Dermatitis is an umbrella term for inflamed, itchy skin. The most common forms are atopic dermatitis (eczema), contact dermatitis (irritant or allergic), and seborrheic dermatitis.

Cannabis has come up as a possible treatment because the skin has its own endocannabinoid system. Cannabinoid receptors (CB1 and CB2) and related enzymes are found on skin cells, sebaceous glands, immune cells, and nerve endings. Strong evidence^[1][2] In theory, activating this system could calm inflammation and itch.

In practice, the human evidence is thin. There are small open-label studies on topical CBD and on palmitoylethanolamide (PEA, an endocannabinoid-like molecule), some lab and animal research, and considerable marketing. There are no large, blinded, randomized trials proving that any cannabis-derived product treats any form of dermatitis. This article walks through what is actually supported, what is plausible but unproven, and what is marketing folklore.

This article is not medical advice. It is a summary of published evidence as of October 2026. If you have dermatitis—especially if it is widespread, infected, painful, or affecting sleep—see a clinician before starting any cannabis product. Tell them what you are using, including topicals.

What probably works (relatively speaking)

Honestly, nothing in cannabis has reached the bar of probably works for dermatitis in the way that topical corticosteroids, calcineurin inhibitors, or newer topical JAK inhibitors have. The closest evidence:

Bland emollient effect of hemp seed oil. Cold-pressed hemp seed oil is a fatty acid-rich vegetable oil (high in linoleic and alpha-linolenic acid), with essentially no THC or CBD. A small randomized crossover trial in atopic dermatitis patients found dietary hemp seed oil improved dryness and itch versus olive oil. Weak / limited^[3] The effect plausibly comes from the fatty acids themselves—standard emollients work by the same mechanism. Don't pay "cannabinoid treatment" prices for vegetable oil.

PEA-containing creams for itch and barrier repair. Palmitoylethanolamide is an endogenous fatty acid amide that interacts with the endocannabinoid system indirectly. A large open-label observational study ("ATOPA") in over 2,000 atopic dermatitis patients reported reduced itch, redness, and topical steroid use with a PEA-containing cream. Weak / limited^[4] Important caveat: open-label (no blinding), no placebo control, and the authors have affiliations with the sponsoring company. Treat the benefit estimates cautiously.

That is the upper end of the current evidence base.

What might work

Topical CBD for inflammation and itch. Laboratory studies show CBD reduces inflammatory cytokines in skin cell cultures and dampens mast cell activation. Weak / limited^[2][5] A small open-label study of a CBD-containing ointment in 20 patients with psoriasis or atopic dermatitis reported improvements in skin parameters and sleep, but included no control group and was not blinded. Weak / limited No adequate randomized trial has tested whether CBD beats a well-formulated moisturizer alone.

Cannabinoids for chronic pruritus in systemic disease. A small uncontrolled study of a cream containing endocannabinoids in patients with uremic pruritus reported reduced itch. Weak / limited^[6] Mechanistically, CB1 activation on peripheral nerve endings can reduce itch signaling. Weak / limited^[1] Case reports describe dronabinol (synthetic THC) reducing intractable pruritus in cholestatic liver disease. Weak / limited^[7] These are not dermatitis studies but related itch conditions.

CBG and other minor cannabinoids. Almost entirely preclinical—interesting in cell models, but no controlled human dermatitis data exist. No data

What doesn't work, or has weak evidence

"CBD cures eczema." or "CBD is a steroid replacement." No. There are no controlled trials supporting cure, reliable remission, or superiority over existing topical agents. No data

Smoking or vaping cannabis to treat eczema. No clinical evidence. Inhaled cannabis raises systemic THC, which has unpredictable effects on immunity, and combustion products are themselves pro-inflammatory. No data

"Indica strains calm skin, sativa strains irritate it." Folklore. The indica/sativa classification does not reliably predict chemistry or effects on any organ system, including skin. See Indica vs Sativa.

High-THC topicals for contact dermatitis. No controlled data exist. THC is lipophilic and absorbs poorly through intact skin from typical topical formulations, so claims of dramatic localized effects should be viewed skeptically. Weak / limited^[8]

Hemp seed oil as a "cannabinoid" treatment. It works modestly as an emollient—but it is not a cannabinoid treatment and contains negligible CBD or THC. Don't pay a premium for it under that label. Disputed

What we don't know

• Whether topical CBD outperforms a well-formulated emollient vehicle alone in a blinded, randomized trial. No adequate RCT exists.
• The appropriate dose of CBD in topical formulations. Products range from <0.1% to >5% with no evidence-based target.
• Whether cannabinoids help, harm, or have no effect on the skin microbiome in atopic dermatitis—a key factor in disease pathology.
• Long-term safety of daily topical cannabinoid use on inflamed, barrier-disrupted skin, which absorbs more drug than healthy skin.
• Whether oral or inhaled cannabis modifies the long-term course of atopic disease. Limited epidemiological data are inconsistent.
• Drug interactions and systemic absorption when topical CBD products are applied over large body surface areas, especially in patients on systemic immunomodulators.
• Whether cannabis-induced contact dermatitis is common enough to outweigh any local anti-inflammatory benefit.

Comparison with standard treatments

Standard dermatology for atopic dermatitis, per American Academy of Dermatology (AAD) and European guidelines, follows an evidence-based ladder: Strong evidence^[9][10]

1. Emollients and trigger avoidance—first line for all patients.
2. Topical corticosteroids—decades of randomized controlled trial evidence, strong and reliable effect, well-characterized risks (skin thinning with prolonged high-potency use).
3. Topical calcineurin inhibitors (tacrolimus, pimecrolimus)—steroid-sparing, well-supported.
4. Topical JAK inhibitors (ruxolitinib) and PDE4 inhibitors (crisaborole)—newer drugs, RCT-supported, good safety profile.
5. Phototherapy and systemic agents—dupilumab, tralokinumab, oral JAK inhibitors for moderate-to-severe disease; robust trial evidence.

No cannabis-derived product has been evaluated in controlled trials at the standard required for dermatology practice. A CBD or PEA cream, at best, functions as a fancy emollient—i.e., it might help at the bottom rung of the ladder, where any decent moisturizer also helps. It is not a substitute for topical steroids, calcineurin inhibitors, JAK inhibitors, or biologics in moderate-to-severe disease.

For contact dermatitis, the standard is identifying and removing the trigger plus short-course topical steroids. There is no good evidence that cannabis products improve on this strategy. Importantly, cannabis itself can cause contact dermatitis.

Risks and adverse effects

Cannabis-induced allergic contact dermatitis. Documented in case reports and small occupational series, particularly in growers, trimmers, and frequent topical users. Sensitization to Cannabis sativa proteins and to terpenes (linalool, limonene) is real. Strong evidence^[11] While uncommon in the general population, it is a genuine risk for frequent users.

Irritant reactions from carrier ingredients. Many CBD topicals contain essential oils, fragrances, and preservatives that themselves trigger dermatitis. Always read the full ingredient list and patch-test if you have sensitive skin.

Product quality and contamination. Independent testing has repeatedly found CBD products mislabeled for potency, some containing detectable THC, pesticides, or heavy metals. Strong evidence^[12] For broken or inflamed skin, contamination poses a greater risk than for intact skin.

Systemic absorption through compromised skin. Inflamed, barrier-disrupted eczematous skin absorbs more drug than healthy skin. Daily whole-body application of a high-potency CBD product is not a zero-exposure intervention and carries small but real risks of systemic effects.

Drug interactions. Oral CBD inhibits liver enzymes (CYP3A4 and CYP2C19) and interacts with many medications. Strong evidence^[13] Topical exposure is usually low but not necessarily zero, especially with large surface areas or high concentrations.

Delay of effective care. The most significant practical harm: people with worsening eczema using cannabis products instead of seeing a dermatologist, leading to infection, severe sleep loss, and permanent scarring.

Sources

How this page was made

Related

• Cannabis and Eczema — Hemp seed oil may help; topical CBD is unproven. Standard treatments remain far more effec...
• Cannabis in Palliative Care — Evidence and risks of cannabis and cannabinoid medicines in serious illness and end-of-lif...
• Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.